SMARTVALUE
Last board
5 directors, 1 auditor, last change in 2025GJ Lifescience management SRL
Director
since 14-07-2021
term until 25-06-2027
listed in the 2025 annual accounts, filed on 25-09-2025
Director
since 28-06-2024
6-year term from 2025
listed in the 2025 annual accounts, filed on 25-09-2025
Director
since 28-06-2024
6-year term from 2025
listed in the 2025 annual accounts, filed on 25-09-2025
Director
since 28-06-2024
6-year term from 2025
listed in the 2025 annual accounts, filed on 25-09-2025
Director
since 28-06-2024
6-year term from 2025
listed in the 2025 annual accounts, filed on 25-09-2025
Statutory auditor, permanent representative Emille Van Callemont
appointed by deed of 20-10-2023
Mandates through the years
9 names, the dashed line is todayGJ Lifescience management SRL
Director
Director
CASTELEIN, Kris Roger
Director
Director
VANDAMME, Stefaan Walter Alphons
Director
Director
EY Réviseurs d'entreprises
Statutory auditor
Statutory auditor
BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
Commissaire pour les comptes statutaires
Commissaire pour les comptes statutaires
GJ LIFESCIENCES MANAGEMENT
Director
Director
JGO
Director (not named in the articles)
Director (not named in the articles)
BoardEarlierRest of the termmandate already running before its first mentionend not dated
Mandates as a list
- GJ Lifescience management SRL
- Director, from 14-07-2021 to date
- CASTELEIN, Kris Roger
- Director, since before 31-03-2024
- GOETHAERT, Stefan Annie Willy Maria
- Director, since before 31-03-2024
- VANDAMME, Stefaan Walter Alphons
- Director, since before 31-03-2024
- WILLEMYNS, Jo Paul Maria Agnès Maurits
- Director, since before 31-03-2024
- EY Réviseurs d'entreprises
- Statutory auditor, from 01-07-2023 to date
- BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
- Commissaire pour les comptes statutaires, appointed by deed of 26-02-2021, until 20-10-2023
- GJ LIFESCIENCES MANAGEMENT
- Director, appointed by deed of 09-09-2021, no longer listed in the 2025 annual accounts
- JGO
- Director (not named in the articles), appointed by deed of 20-01-2021, until 14-07-2021
- Director (not named in the articles), appointed by deed of 20-01-2021, no longer listed in the 2025 annual accounts
Control
Capital
- Capital
- €61,500
- Shares
- 250
- Contribution per share
- €246
- Equity per share
- €9,771 in 2025
- Source
- deed of 12-02-2025
Owners through the years
as the annual accounts name themOwners as a list
- NEWPHARMA GROUP
- SKYCO
Source: shareholder structure in its own accounts, parent in its own accounts, lists of holdings in the owners' accounts
Articles of association
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 20-01-2021 (in French)
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Conseil d'administration, six ans au plus”“Peut nommer un vice-président, conseil d'administration parmi ses membres”“Conseil détermine s'ils agissent seul ou conjointement, à tout temps”deed of 12-02-2025 (in French)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Third Tuesday of September at 15:00deed of 12-02-2025 (in French)
Capital transactions
Shareholders according to the deeds
Stated in the deed
deed of 04-09-2025 ↗
- Newpharma Group (BE 0684.465.652) all shares
Capital over time
- 04-09-2025 Capital stated in the deed · 250 shares
- 12-02-2025 Capital stated in the deed · €61,500 · 250 shares
- 20-01-2021 Converted to unavailable equity